The stock of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) increased by $0.02 on Wednesday to $1.65, up 1.23 percent. The last five days have seen an average of 1,027,455 shares of common stock traded. 14 times new highs were reached in the current year, with a fall of -$0.2600. The average number of shares traded over the last 20 days was 1,641,969, while the average volume over the last 50 days totaled 2,176,449.
LXRX stock dropped -26.01% since last month. On 08/16/23, the company’s shares reached a one-month low of $1.6100. The stock touched a high of $3.79 on 05/05/23, after rallying from a low of $1.62 in 52 weeks. The price of LXRX stock has declined by -13.61% or -$0.2600 this year, reaching a new high 14 times. Still, the stock price is down -56.45% from the 52-week high.
Insider Transactions
LXRX stock investors should be aware that Lexicon Pharmaceuticals Inc. (LXRX) stock had its last reported insider trading activity 12 days ago on Aug 04. On Aug 04, VP, Human Resources McDermott Wendy acquired 6,000 shares at $1.84 each. This transaction resulted in the insider spending $11,040. On Jun 29, COATS LONNEL added 10,000 shares at a price of US$2.16. After the transaction, the insider now owns 814,359 shares. Chief Executive Officer COATS LONNEL had earlier bought 10,000 shares on Jun 26 for $2.18 a share. The transaction was completed for $21,792.
Valuation Metrics
Beta for the stock is 1.19. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1004.56, the price-to-book (PB) ratio of 1.81.
Financial Health
For the three months ended June 29, Lexicon Pharmaceuticals Inc.’s quick ratio was 10.10, while its current ratio was 10.10, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.53, and the total debt to equity ratio is 0.53. As far as profitability goes, gross margin for the trailing twelve months is 98.00% percent. Based on annual data, it had gross profit of $0.14 million and revenue of $0.14 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. LXRX’s return on assets (ROA) during the last 12 months has been -60.40%. In the meantime, the return on equity (ROE) for the last 12 months was -97.60%.
Earnings Surprise
According to Lexicon Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29, it had $98.77 million in total debt versus $154.47 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.32 million, while revenues rose by 100.0% to $0.0. It was predicted that Lexicon Pharmaceuticals Inc.’s quarterly earnings would be -$0.22, but it ended up being -$0.17, beating the consensus by -29.40%. EBITDA was -$43.82 million for the quarter. At the end of Lexicon Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 130.36 million, while its total debt was $105.55 million. Equity owned by shareholders amounts to $244.93 million.
Technical Picture
Here’s a quick look at Lexicon Pharmaceuticals Inc.’s (LXRX) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 28.86%, suggesting the stock is oversold, with a 67.07% historical volatility rate.
The stochastic %K and %D were 6.77% and 8.66% respectively, while the average true range (ATR) was 0.1060. Based on the 14-day stochastic reading of 9.52%, the RSI (14) reading is 31.14%. On the 9-day MACD Oscillator, the stock is at -0.0678, and the 14-day reading is at -0.1464.
Analyst Ratings
In its analyst report released on March 07, 2023, Jefferies began covering Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). The stock was rated as a Hold by the brokerage firm. Analysts have assigned Lexicon Pharmaceuticals Inc. (LXRX) an Overweight rating. LXRX is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 2 others recommend it as a buy.
What is LXRX’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.30 and $10.00, with a median target price of $5.00. In analyzing these forecasts, the average price target given by analysts for Lexicon Pharmaceuticals Inc. (LXRX) is $5.77.
